Interestingly, CD44-STn contributes to cancer tolerogenic immune responses and cell invasion, whereas MUC16-STn is expressed by subgroups of patients that do not respond to cisplatin-based therapeutics [21, 22]. This evidence concerns the gene EEF1A2 and cancer.